目前肺癌已成为全世界范围内发病率和病死率最高的恶性肿瘤,且呈逐年上升趋势,其中非小细胞肺癌占80%~85%,75%~80%的患者就诊时已处于Ⅲ~Ⅳ期[1]。最近几年,大量的研究发现血浆D-二聚体的水平与非小细胞肺癌的病情变化、治疗效果、预后等存在非常密切的关系[2]。研究表明,血浆D-二聚体的水平可以作为观察患者病情、判断预后、评价化疗疗效的一个有效指标[3]。本文通过 At present, lung cancer has become the world’s highest incidence and mortality of malignant tumors, and showed an upward trend year by year, of which 80% to 85% of non-small cell lung cancer, 75% to 80% of patients at the time of treatment has been in Ⅲ ~ Ⅳ Period [1]. In recent years, a large number of studies have found that there is a very close relationship between the level of plasma D-dimer and the change of disease, treatment effect and prognosis of non-small cell lung cancer [2]. Studies have shown that the level of plasma D-dimer can be used as observation of patient’s condition, prognosis, evaluation of the efficacy of chemotherapy is an effective indicator [3]. This article is adopted